

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT3654843

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
NATURAL PHARMA CANADA, ULC	01/12/2010
NATURAL PHARMACEUTICALS, INC.	01/12/2010
RECEIVING PARTY DATA	
Name:	PHYTON, INC.
Street Address:	318 MCCULLOUGH AVENUE
City:	SAN ANTONIO
State/Country:	TEXAS
Postal Code:	78215
PROPERTY NUMBERS Total: 2	
Property Type	Number
Application Number:	12705247
Application Number:	14188416
CORRESPONDENCE DATA	
Fax Number:	(512)536-4598
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	5125363050
Email:	aoipdocket@nortonrosefulbright.com
Correspondent Name:	NORTON ROSE FULBRIGHT US LLP
Address Line 1:	98 SAN JACINTO BOULEVARD
Address Line 2:	SUITE 1100
Address Line 4:	AUSTIN, TEXAS 78701
ATTORNEY DOCKET NUMBER:	DFBP:064US.C2 & C3
NAME OF SUBMITTER:	SEAN MINORINI
SIGNATURE:	/Sean Minorini/
DATE SIGNED:	12/11/2015
Total Attachments: 3	
source=DFBP_ASSIGNMENT_3#page1.tif	
source=DFBP_ASSIGNMENT_3#page2.tif	
source=DFBP_ASSIGNMENT_3#page3.tif	

PATENT ASSIGNMENT

WHEREAS, Natural Pharma Canada, ULC, a Nova Scotia unlimited liability corporation and Natural Pharmaceuticals, Inc., a Delaware corporation (hereinafter collectively, the "ASSIGNOR"), is(are) the owner(s) of the patents and patent applications identified on Exhibit A (collectively, the "Patents");

AND WHEREAS, Phyton, Inc., a Delaware corporation (hereinafter the "ASSIGNEE"), is desirous of acquiring all right, title and interest in and to the Patents;

NOW, THEREFORE, FOR GOOD AND VALUABLE CONSIDERATION, the receipt, sufficiency and adequacy of which are hereby acknowledged, ASSIGNOR does hereby:

IRREVOCABLY SELL, ASSIGN, AND TRANSFER to the ASSIGNEE effective October 12th, 2009, the entire right, title and interest for the United States and all foreign countries in and to any and all improvements which are disclosed in the Patents, including but not limited to the right to sue for injunctions and/or damages for any past, ongoing, and/or future infringement;

AUTHORIZE AND REQUEST the issuing authority to issue any and all United States and foreign patents granted on such improvements to the ASSIGNEE;

WARRANT AND COVENANT that no assignment, grant, mortgage, license or other agreement affecting the rights and property herein conveyed has been or will be made to others by the undersigned, and that the full right to convey the same as herein expressed is possessed by the undersigned; and

COVENANT, when requested and at the expense of the ASSIGNEE, to carry out in good faith the intent and purpose of this assignment, the undersigned will execute all divisional, continuing, substitute, renewal, reissue, and all other patent applications on any and all such improvements; execute all rightful oaths, declarations, assignments, powers of attorney and other papers; communicate to the ASSIGNEE all facts known to the undersigned relating to such improvements and the history thereof; and generally do everything possible which the Assignee shall consider desirable for vesting title to such improvements in the Assignee, and for securing, maintaining and enforcing proper patent protection for such improvements.

TO BE BINDING on the heirs, assigns, representatives and successors of the undersigned and extend to the successors, assigns and nominees of the ASSIGNEE.

NATURAL PHARMA CANADA, ULC

Signature: _____




Date: January 12, 2010

Name: Roland R. Franke

Title: CEO

NATURAL PHARMACEUTICALS, INC.

Signature: _____



Date: January 12, 2010

Name: Roland R. Franke

Title: CEO

Exhibit A

All U.S. and non-U.S. patents and applications owned by the ASSIGNOR as of the date first written above, including, but not limited to, the patents and applications (and any related continuing, continuation, continuation-in-part, divisional, renewal, reissue, substitute patents and applications thereof) identified in the following table:

U.S. Patents	U.S. Applications	Non-U.S. Patents/Applications		
5,334,732	07/909,080	Argentina	Europe	PCT/International
5,336,684	07/973,076	P04-01-00896	EP 696279	PCT/US1993/10580
5,356,928	08/323,275		EP 0755387	PCT/US1994/04519
5,364,947	08/331,682	Australia	EP 0668862	PCT/US1994/10525
5,412,116	08/401,711	AU 1994067735	EP 95915472.5	PCT/US1995/03975
5,449,790	08/431,906	AU 1994078367	EP 95915543.3	PCT/US1995/04172
5,629,433	08/617,391	AU 1995022342	EP 96907021.8	PCT/US1995/008849
5,679,807	10/522,696	AU 1995022392	EP 96909628.8	PCT/US1996/001322
5,792,877	10/549,490	AU 1995031278	EP 03728345.4	PCT/US1996/003242
5,808,113	11/173,477	AU 1996050210	EP 1497276	PCT/US2004/008055
5,892,063	11/196,950	AU 1996053057	EP 03767262.3	PCT/US2003/010556
6,956,123	11/764,362	AU 2004221834	EP 03815018.1	PCT/US2003/010557
7,176,325	60/370,252	AU 2003234689	EP 04707837.3	PCT/US2003/024666
7,220,872	60/370,583	AU 2003226287	EP 04757522.0	PCT/US2003/041824
	60/401,191	AU 2003256861		PCT/US2003/041774
	60/437,237	AU 2003303565	Germany	PCT/US2004/003259
	60/437,434	AU 2003300164	DE 69402311	
	60/444,847	AU 19940055476	DE 69511257	
	60/455,377	AU 685119	DE 69332223	
	60/456,478	AU 694627	DE 60323079	
	61/031,467			
		Canada	Japan	
		CA 2161138	JP 94-524451	
		CA 2187337	JP 3759602	
		CA 2148943	JP 696279	
		CA 2187191	JP 3878204	
		CA 2211799	JP 08-523705	
		CA 2214993	JP 08-527756	
		CA 2519474	JP 2006-507246	
		CA 2495476	JP 2004-526071	
		CA 2512095	JP 2007-76064	
		CA 2512170		
		China	Spain	
		CN 200480013498.X	ES 2181706	
		CN 03823660.5	ES 2312800	
			Taiwan	
			93107087	

TRF

PATENT